Gruppo Lepetit S.p.a.

Merrell Dow Pharmaceuticals

Biosearch Italia S.p.a.

Angelo Borghi

Carolina Coronelli

Adriano Malabarba

Bruno Cavalleri

Paolo Strazzolini

Giancarlo Lancini

Piero Antonini

Enrico Selva

Giovanni Cassani

Grazia Beretta

Maurizio Denaro

Francesco Parenti

Beth P Goldstein

Giorgio Pirali

Giovanni Mistrello

Luciano Gastaldo

Vittorio Arioli

Raffaele Palumbo

Rosa Pallanza

The present invention relates to a method for selectively enhancing the production of factors A.sub.2 and/or A.sub.3 of antibiotic A/16686 either to isolate these single components or to enrich the complex in one or both the above components, which comprises adding an appropriate precursor of the desired antibiotic factor to an A/16686 producing culture during fermentation.

Method for selectively increasing the ratio of single major components

The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.

Glycopeptide antibiotics

The object of this invention are de-mannosylated teicoplanin derivatives which can be obtained in good yield by microbiological transformation with cultures of Nocardia orientalis NRRL 2450 or Streptomyces candidus NRRL 3218.

Process for the preparation of de-mannosyl teicoplanin derivatives

The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Composition of antibiotic L 17054 and a method for the treatment of

The present invention relates to new teicoplanin-like antibiotics differing from the parent compound in the length of the acyl group. The compounds of the invention are obtained according to a microbiological process and possess an antimicrobiol activity mainly against gram positive bacteria.

Teicoplanin-like derivatives

The oject of this invention are de-mannosylated teicoplanin derivatives which can be obtained in good yield by microbiological transformation with cultures of Nocardia orientalis NRRL 2450 or Streptomyces candiodus NRRL 3218.

De-mannosyl teicoplanin derivatives

Process for preparing antibiotic L 17054

The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Antibiotic A 40926 complex and its pure factors PA, PB, A, B and B.sub.0

The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L 17046. This antibiotic substance is obtained from the known antibiotic substance called teicoplanin (formerly teichomycin) by chemical treatment. The new compound possesses antimicrobial activity expecially against gram-positive bacteria.

Antibiotic L 17046 and process for preparing it

The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L 17046. This antibiotic substance is obtained from the known antibiotic substance called teicoplanin (formerly teichomycin) by chemical treatment. The new compound possesses antimicrobial activity especially against gram-positive bacteria.

Glycopeptide antibiotic L 17046

Glycopeptide antibiotic L 17054

The invention refers to an individual antibiotic substance selected from the group consisting of Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 in substantially pure form, and to the method of producing them by recovery from Teichomycin A.sub.2, a known antibiotic substance, by means of high-efficiency chromatographic methods. The single pure Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 are biologically distinguishable from Teichomycin A.sub.2 in that they have a higher degree of antibiotic activity against susceptible microorganisms.

Teichomycin A.sub.2 pure single factors 1, 2, 3, 4 and 5 and method for

A new antibiotic, designated S/433, is disclosed which is produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces. This new antibiotic is active against gram-positive and gram-negative bacteria and is also active in inhibiting the growth of transplanted tumors.

Growing community of inventors

Milan, Italy

Angelo Borghi